arrow
K

Keith D. Wilner

Pfizer
H指数:59
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report

更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

2025-06-040
OAAI
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
2024-02-150
OAAI
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer

PF-06747775单药或联合帕博西尼治疗表皮生长因子受体突变型晚期非小细胞肺癌的1b/2期研究

2022-06-036
OA
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men
2021-11-1925
PRE
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration
2021-11-0136
OA
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

一项比较达克替尼和吉非替尼作为一线治疗晚期非小细胞肺癌和EGFR激活突变患者的随机研究中更新的总生存期

DRUGS
IF14.4
2020-12-1774
OAAI
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1, TRIO-18)

palbociclib联合来曲唑与单独来曲唑一线治疗ER /HER2-advanced乳腺癌的随机2期研究的总生存期结果 (PALOMA-1,TRIO-18)

2020-07-18110
OAAI
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
2020-01-13281
OAAI